Literature DB >> 1860265

Treatment of idiopathic nephrotic syndrome with cyclosporin A in children.

P Niaudet1, M Broyer, R Habib.   

Abstract

Cyclosporin A (CyA, Sandimmun) was given to 71 children with idiopathic nephrotic syndrome, 45 of whom were steroid-dependent with signs of steroid toxicity, and 23 who were steroid-resistant. Cyclosporin A was effective in 80% of the steroid-dependent patients, allowing cessation of corticosteroid treatment. However, most of these patients relapsed when CyA was tapered or withdrawn. In these patients, CyA may be required for long periods of time. Conversely, CyA was less effective in steroid-resistant patients; only 7% achieved remission with CyA alone. Cyclosporin A in association with prednisone may be an effective alternative as 8 out of 14 patients entered remission with this treatment combination. Serial renal biopsies were performed in 43 patients to evaluate the potential nephrotoxicity of the treatment. Eighteen patients developed significant tubulointerstitial lesions which were attributable to CyA nephrotoxicity. The risk of developing chronic nephrotoxicity appears to be higher in steroid-resistant patients, and was not related to the duration of treatment. Cyclosporin A nephrotoxicity can develop in patients with normal renal function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860265

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  27 in total

Review 1.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Debbie S Gipson; Elisabeth M Hodson
Journal:  Pediatr Nephrol       Date:  2012-10-03       Impact factor: 3.714

2.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

3.  Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J N Tobin; J Bernstein; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  In what order should one introduce cyclophosphamide or chlorambucil, cyclosporine or levamisole in a child with steroid-dependent frequently relapsing nephrotic syndrome?

Authors:  J Brodehl
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

5.  Hodgkin's disease following steroid-resistant idiopathic nephrotic syndrome.

Authors:  G Deschênes; C Allard; S Benoit; O Lejars; J P Lamagnére; H Nivet
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

Review 6.  Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians.

Authors: 
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

7.  Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome.

Authors:  Severin Kengne-Wafo; Laura Massella; Francesca Diomedi-Camassei; Alessandra Gianviti; Marina Vivarelli; Marcella Greco; Gilda Rita Stringini; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 8.237

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide.

Authors:  P Cochat; A Kassir; S Colon; C Glastre; B Tourniaire; B Parchoux; X Martin; L David
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

10.  Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.

Authors:  J McCauley; R Shapiro; D Ellis; H Igdal; A Tzakis; T E Starzl
Journal:  Nephrol Dial Transplant       Date:  1993       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.